Imbruvica prices compared U.S. vs select countries 2020

In 2020, both the estimated U.S. net price and gross price for a one-month supply (90 capsules) of Imbruvica Oral Capsule (140mg) were roughly two times higher than gross prices paid in the comparison countries. Imbruvica is a cancer medicine used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. This statistic shows Imbruvica's net and gross prices in the United States compared to gross prices in Australia, Canada, and France as of 2020.

Estimated U.S. prices of Imbruvica compared to prices in Australia, Canada, and France as of 2020*

Characteristic	Price in U.S. dollars
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

March 2021

More information

Region

Australia, Canada, France, United States

Survey time period

as of January 2020

Supplementary notes

* Prices are for a monthly supply of Imbruvica Oral Capsules 140mg (90 capsules).
Estimated U.S. net prices reflect confidential rebates and other price concessions, information on such discounts was not publicly available for the comparison countries. Thus, the actual differences between U.S. prices and those of the other countries were likely larger than GAO estimates in this statistic.

Prices for selected comparison countries — Australia, Canada (Ontario), and France— were prices listed on their respective public formularies from January 2020 and were converted to U.S. dollars at the relevant monthly Federal Reserve rates.

Citation formats